Kaliumchlorid/Glucose B. Braun (Glucose, Anhydrous, Potassium Chloride)

Kaliumchlorid/Glucose B. Braun is employed in clinical settings to address electrolyte and energy needs across several conditions.

• Hypokalemia: restores serum potassium levels to normal ranges.
• Potassium deficiency: replenishes depleted potassium stores.
• Energy supplementation: delivers glucose for immediate metabolic use.
• Parenteral nutrition: contributes essential electrolytes and calories as part of total intravenous nutrition.

• The potassium chloride component dissociates to release K⁺ ions, directly increasing extracellular potassium concentration and supporting cellular membrane potential. The glucose anhydrous component is rapidly metabolized, providing a source of energy for glycolysis and ATP production. Delivered intravenously, both agents bypass gastrointestinal absorption, allowing immediate correction of electrolyte deficits and rapid caloric support.

Adverse reactions may occur with any intravenous preparation. Monitoring and appropriate infusion rates help minimise risk.

Common Side Effects

• Infusion site irritation or phlebitis.
• Mild hyperglycemia.
• Transient hyperkalemia.
• Nausea or vomiting.
• Headache.
• Slight hypotension during rapid infusion.

Serious or Rare Side Effects

• Severe hyperkalemia leading to cardiac arrhythmia.
• Anaphylactic or severe allergic reaction.
• Marked hyperglycemia with osmotic diuresis.
• Metabolic acidosis.
• Thrombophlebitis or deep vein thrombosis.
• Life‑threatening electrolyte imbalance.

Careful assessment and monitoring are essential when using this intravenous solution.

• Baseline assessment: verify serum potassium and glucose levels before initiation.
• Cardiac monitoring: observe rhythm during and after infusion, especially in patients with cardiac disease.
• Renal impairment: adjust infusion rate and total dose as kidneys may excrete potassium more slowly.
• Diabetic patients: monitor blood glucose closely and adjust insulin therapy as needed.
• Infusion speed: avoid rapid administration to reduce risk of cardiovascular events.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before prescribing.

Major Interactions (Avoid)

• ACE inhibitors or ARBs: may potentiate hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): increase risk of elevated serum potassium.
• NSAIDs: can reduce renal potassium excretion, heightening hyperkalemia risk.
• Insulin therapy: concurrent high glucose infusion may counteract insulin’s glucose‑lowering effect.
• Digoxin: elevated potassium levels can alter digoxin toxicity profile.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask symptoms of hypoglycemia.
• Other IV fluids containing electrolytes: adjust overall electrolyte load.
• Corticosteroids: can influence potassium balance.
• Loop diuretics: may require potassium supplementation adjustments.
• Anticoagulants: monitor for infusion‑related thrombophlebitis.